Pharma Giants Team Up to Develop Digital Endpoint Toolkit for Reimbursement Decision-Making

April 4, 2022

As the pharmaceutical industry gears up to make shifts in trial design towards the increased use of real-world evidence (RWE), major pharmaceutical companies have partnered with the nonprofit Digital Medicine Society to develop a new toolkit to make reimbursement decisions. The toolkit relies on newly available digital endpoints from medical devices and health apps.

According to Heather Landi of Fierce Healthcare, “The open-access 3Ps (pharma, payers and patients) toolkit recognizes that pharma and payers must work together to define the evidence needed to support the value of new, digitally generated data to patients’ lives. The resources were developed following a series of workshops convening global regulators, health technology assessment (HTA) bodies, public and private payers, industry sponsors, health economists, and clinical and patient experts, according to the organization.”